Allegro Ophthalmics

Allegro Ophthalmics LLC is committed to redefining the retina space through integrin inhibition therapy, a potentially disruptive drug in the market for treating retinal diseases. Allegro's lead investigational drug, risuteganib (Luminate®), a broad-spectrum integrin inhibitor, modulates downstream oxidative stress at its source while impacting all four oxidative stress pathways that lead to retinal diseases such as diabetic macular edema (DME) and non-diabetic age-related macular degeneration (dry AMD).